Confirmed cases in the Bundibugyo Ebola outbreak reached 9,847, with 4,761 confirmed deaths, as of Oct. 23, according to the CDC's situation summary. Nearly all are in the Democratic Republic of the Congo, which reports 9,816 cases and 4,757 deaths, and nearly half of confirmed patients have died.

Two new developments change the picture. On Oct. 23, WHO announced the outbreak's first vaccine clinical trial, launched in Bunia, the capital of hard-hit Ituri province. And CDC now lists confirmed cases in Kenya and Nigeria, while warning that starting after 11:59 p.m. Eastern on Nov. 3, international passengers flying to the U.S. must attest they have not been in Congo in the previous 21 days.

The U.S. public risk has not changed — CDC says no U.S. cases are linked to the outbreak and the risk to Americans and travelers "remains low." The new rules matter most for people traveling to or through Central and East Africa, airline passengers and health workers.

A Rare Virus With No Proven Vaccine

Bundibugyo virus is one of several species that cause Ebola disease, and it has been seen only rarely. It was first identified in 2007 in western Uganda, and Congo had a smaller Bundibugyo outbreak in 2012, according to the UK Health Security Agency. UKHSA calls the current event the largest Bundibugyo outbreak recorded and the second-largest Ebola outbreak to date.

That history is the core problem — the licensed Ebola vaccine, Ervebo, and approved antibody treatments target the Zaire species, which caused the 2014-2016 West Africa epidemic. Nobody yet knows how well they protect against Bundibugyo.

The new trial, called Tumaini, is designed to find out. It uses ring vaccination, immunizing contacts of patients, and will include pregnant women and children 12 and older, Al Jazeera reported. Participants are first receiving Ervebo to test cross-protection. Two Bundibugyo-specific candidates, from the University of Oxford and Moderna, are expected to join soon with funding from CEPI. WHO Director-General Tedros Adhanom Ghebreyesus said the trial will show "whether any of the vaccine candidates designed for Bundibugyo virus work."

Conflict and Cross-Border Spread

The outbreak is concentrated in eastern Congo, where armed conflict, displacement and heavy trade traffic complicate response. As of Oct. 11, UKHSA counted cases in 65 health zones across seven provinces. Ituri had 6,695 cases with new cases declining, while transmission persisted in North Kivu, with 1,911 cases, and Haut-Uele, with 383.

Nature World News previously reported on violence affecting responders, including a burned displacement camp near Bunia that held an Ebola transit center and strikes by unpaid health workers. Insecurity limits contact tracing, which means chains of infection can be missed.

The virus has also traveled. Uganda recorded 20 cases before WHO and Africa CDC declared its outbreak over on Aug. 27. Kenya has nine confirmed cases and two deaths, according to CDC, after a traveler from Congo flew into Nairobi in early October. Nigeria has one confirmed case, the first in West Africa, and France had one case that has recovered. Each imported case shows how road and air travel can carry the virus across borders within days.

U.S. Readiness and Travel Rules

CDC's measures focus on stopping importation. Travelers who were in Congo within 21 days of a flight cannot board commercial flights to the U.S., and U.S. citizens and nationals coming from Congo must stay outside the country for 21 days first. Those who were in Uganda or South Sudan must enter through designated airports for enhanced screening. About 500 CDC staff are working on the response, including more than 120 deployed abroad.

CDC also briefed U.S. clinical laboratories on the outbreak during its Oct. 19 Laboratory Outreach Communication System call, part of keeping hospital labs prepared to handle suspect specimens safely.

CDC's formal risk assessment, last updated Sept. 8, rates the general U.S. risk as low and states that the "likelihood of infection is extremely low," though any case would have high impact.

Travel guidance is tiered. CDC advises avoiding all travel to Ituri and North Kivu, reconsidering nonessential travel to Haut-Uele and Tshopo, and taking enhanced precautions elsewhere in Congo and in Uganda.

Risks, Warning Signs and What Comes Next

The people at greatest risk are health workers and family caregivers in affected areas, who handle body fluids, along with people attending unsafe burials. For U.S. residents, risk is concentrated among travelers returning from affected regions and the clinicians who see them.

Anyone who develops fever, severe headache, muscle pain, vomiting, diarrhea, or unexplained bleeding within 21 days of being in an affected country should call a health care provider before arriving, so the facility can prepare. People without such travel history do not need to take special precautions.

Key unknowns include how well Ervebo protects against Bundibugyo, how much transmission goes undetected in insecure areas, and how the Nigerian patient was infected. Trial results will take time, since efficacy depends on enough exposures among participants.

Developing Story Timeline

Oct. 24, 2026: CDC updates its situation summary to 9,847 confirmed cases and 4,761 deaths through Oct. 23.

Oct. 23, 2026: WHO announces the Tumaini vaccine trial in Bunia.

Oct. 19, 2026: CDC briefs U.S. clinical labs on the outbreak.

Oct. 6, 2026: Kenya reports its first case, a traveler from Congo.

Aug. 27, 2026: WHO and Africa CDC declare Uganda's outbreak over.

May 15, 2026: Congo and Uganda declare the outbreak.

The bottom line: the outbreak is nearing 10,000 confirmed cases and has reached West Africa, but the first vaccine trial has begun in its epicenter. U.S. risk remains low, and travelers should watch for the Nov. 3 attestation requirement.

What Readers Want to Know

How large is the outbreak? CDC counts 9,847 confirmed cases and 4,761 deaths through Oct. 23, nearly all in Congo.

Why is it hard to stop? Bundibugyo is rare, no vaccine is proven against it, and conflict in eastern Congo limits tracing and care.

What is the new vaccine trial? The Tumaini trial in Bunia is testing Ervebo for cross-protection, with Bundibugyo-specific candidates expected to join.

Which countries have reported cases? Congo, Uganda, Kenya, Nigeria, and France, according to CDC. Uganda's outbreak has been declared over.

Is the U.S. at risk? CDC rates the risk to the American public as low and reports no U.S. cases.

What changes for travelers on Nov. 3? After 11:59 p.m. Eastern, U.S.-bound international passengers must attest that they have not been in Congo within 21 days.